Octreotide in the treatment of intestinal lymphangiectasia.
Identifieur interne : 00BC79 ( Ncbi/Curation ); précédent : 00BC78; suivant : 00BC80Octreotide in the treatment of intestinal lymphangiectasia.
Auteurs : A B Ballinger [Royaume-Uni] ; M J FarthingSource :
- European journal of gastroenterology & hepatology [ 0954-691X ] ; 1998.
Descripteurs français
- KwdFr :
- Adolescent, Agents gastro-intestinaux (administration et posologie), Agents gastro-intestinaux (usage thérapeutique), Humains, Lymphangiectasie intestinale (), Lymphangiectasie intestinale (traitement médicamenteux), Mâle, Octréotide (administration et posologie), Octréotide (usage thérapeutique), Récidive, Épanchement pleural ().
- MESH :
- administration et posologie : Agents gastro-intestinaux, Octréotide.
- traitement médicamenteux : Lymphangiectasie intestinale.
- usage thérapeutique : Agents gastro-intestinaux, Octréotide.
- Adolescent, Humains, Lymphangiectasie intestinale, Mâle, Récidive, Épanchement pleural.
English descriptors
- KwdEn :
- Adolescent, Gastrointestinal Agents (administration & dosage), Gastrointestinal Agents (therapeutic use), Humans, Lymphangiectasis, Intestinal (complications), Lymphangiectasis, Intestinal (drug therapy), Male, Octreotide (administration & dosage), Octreotide (therapeutic use), Pleural Effusion (complications), Recurrence.
- MESH :
- chemical , administration & dosage : Gastrointestinal Agents, Octreotide.
- chemical , therapeutic use : Gastrointestinal Agents, Octreotide.
- complications : Lymphangiectasis, Intestinal, Pleural Effusion.
- drug therapy : Lymphangiectasis, Intestinal.
- Adolescent, Humans, Male, Recurrence.
Abstract
Primary intestinal lymphangiectasia is characterized by dilated small bowel lymphatics and loss of lymph into the bowel lumen resulting in hypoproteinaemia and oedema. Some patients have a more generalized lymphatic abnormality associated with lymphoedema of the limbs and chylous pleural effusions. There is no specific treatment although enteric protein loss may decrease with a low-fat diet. This report describes a patient with severe primary intestinal lymphangiectasia, associated with limb oedema and recurrent pleural effusions, who responded to treatment with octreotide. Before starting octreotide she required weekly intravenous albumin infusions to maintain the serum albumin above 20 g/l. Bilateral pleural effusions repeatedly reaccumulated despite pleurectomy and subsequently tetracycline pleurodesis. Treatment with octreotide, 200 microg twice daily, resulted in a reduction in enteric protein loss from 16 to 4.1% in 5 days (normal less than 1%) and the serum albumin was maintained between 22 and 26 g/l without the need for albumin infusion. Oedema in the arms resolved completely and the pleural effusions did not reaccumulate. The mechanism of action of octreotide in this condition appears to be due to a reduction in gut protein loss and another, as yet unidentified, action.
PubMed: 9744700
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :004E32
- to stream PubMed, to step Curation: Pour aller vers cette notice dans l'étape Curation :004E32
- to stream PubMed, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :004E32
- to stream Ncbi, to step Merge: Pour aller vers cette notice dans l'étape Curation :00BC79
Links to Exploration step
pubmed:9744700Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Octreotide in the treatment of intestinal lymphangiectasia.</title><author><name sortKey="Ballinger, A B" sort="Ballinger, A B" uniqKey="Ballinger A" first="A B" last="Ballinger">A B Ballinger</name><affiliation wicri:level="1"><nlm:affiliation>Digestive Diseases Research Centre, St Bartholomew's and The Royal London School of Medicine and Dentistry, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Digestive Diseases Research Centre, St Bartholomew's and The Royal London School of Medicine and Dentistry</wicri:regionArea><wicri:noRegion>St Bartholomew's and The Royal London School of Medicine and Dentistry</wicri:noRegion></affiliation></author><author><name sortKey="Farthing, M J" sort="Farthing, M J" uniqKey="Farthing M" first="M J" last="Farthing">M J Farthing</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="1998">1998</date><idno type="RBID">pubmed:9744700</idno><idno type="pmid">9744700</idno><idno type="wicri:Area/PubMed/Corpus">004E32</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">004E32</idno><idno type="wicri:Area/PubMed/Curation">004E32</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">004E32</idno><idno type="wicri:Area/PubMed/Checkpoint">004E32</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">004E32</idno><idno type="wicri:Area/Ncbi/Merge">00BC79</idno><idno type="wicri:Area/Ncbi/Curation">00BC79</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Octreotide in the treatment of intestinal lymphangiectasia.</title><author><name sortKey="Ballinger, A B" sort="Ballinger, A B" uniqKey="Ballinger A" first="A B" last="Ballinger">A B Ballinger</name><affiliation wicri:level="1"><nlm:affiliation>Digestive Diseases Research Centre, St Bartholomew's and The Royal London School of Medicine and Dentistry, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Digestive Diseases Research Centre, St Bartholomew's and The Royal London School of Medicine and Dentistry</wicri:regionArea><wicri:noRegion>St Bartholomew's and The Royal London School of Medicine and Dentistry</wicri:noRegion></affiliation></author><author><name sortKey="Farthing, M J" sort="Farthing, M J" uniqKey="Farthing M" first="M J" last="Farthing">M J Farthing</name></author></analytic><series><title level="j">European journal of gastroenterology & hepatology</title><idno type="ISSN">0954-691X</idno><imprint><date when="1998" type="published">1998</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent</term><term>Gastrointestinal Agents (administration & dosage)</term><term>Gastrointestinal Agents (therapeutic use)</term><term>Humans</term><term>Lymphangiectasis, Intestinal (complications)</term><term>Lymphangiectasis, Intestinal (drug therapy)</term><term>Male</term><term>Octreotide (administration & dosage)</term><term>Octreotide (therapeutic use)</term><term>Pleural Effusion (complications)</term><term>Recurrence</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adolescent</term><term>Agents gastro-intestinaux (administration et posologie)</term><term>Agents gastro-intestinaux (usage thérapeutique)</term><term>Humains</term><term>Lymphangiectasie intestinale ()</term><term>Lymphangiectasie intestinale (traitement médicamenteux)</term><term>Mâle</term><term>Octréotide (administration et posologie)</term><term>Octréotide (usage thérapeutique)</term><term>Récidive</term><term>Épanchement pleural ()</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Gastrointestinal Agents</term><term>Octreotide</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Gastrointestinal Agents</term><term>Octreotide</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Agents gastro-intestinaux</term><term>Octréotide</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Lymphangiectasis, Intestinal</term><term>Pleural Effusion</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Lymphangiectasis, Intestinal</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Lymphangiectasie intestinale</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Agents gastro-intestinaux</term><term>Octréotide</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adolescent</term><term>Humans</term><term>Male</term><term>Recurrence</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adolescent</term><term>Humains</term><term>Lymphangiectasie intestinale</term><term>Mâle</term><term>Récidive</term><term>Épanchement pleural</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Primary intestinal lymphangiectasia is characterized by dilated small bowel lymphatics and loss of lymph into the bowel lumen resulting in hypoproteinaemia and oedema. Some patients have a more generalized lymphatic abnormality associated with lymphoedema of the limbs and chylous pleural effusions. There is no specific treatment although enteric protein loss may decrease with a low-fat diet. This report describes a patient with severe primary intestinal lymphangiectasia, associated with limb oedema and recurrent pleural effusions, who responded to treatment with octreotide. Before starting octreotide she required weekly intravenous albumin infusions to maintain the serum albumin above 20 g/l. Bilateral pleural effusions repeatedly reaccumulated despite pleurectomy and subsequently tetracycline pleurodesis. Treatment with octreotide, 200 microg twice daily, resulted in a reduction in enteric protein loss from 16 to 4.1% in 5 days (normal less than 1%) and the serum albumin was maintained between 22 and 26 g/l without the need for albumin infusion. Oedema in the arms resolved completely and the pleural effusions did not reaccumulate. The mechanism of action of octreotide in this condition appears to be due to a reduction in gut protein loss and another, as yet unidentified, action.</div></front></TEI></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/Ncbi/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 00BC79 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd -nk 00BC79 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= Ncbi
|étape= Curation
|type= RBID
|clé= pubmed:9744700
|texte= Octreotide in the treatment of intestinal lymphangiectasia.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/RBID.i -Sk "pubmed:9744700" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd \
| NlmPubMed2Wicri -a LymphedemaV1
| This area was generated with Dilib version V0.6.31. |  |